CRIS · Curis, Inc.

Curis, Inc. faces imminent delisting risk from Nasdaq Capital Market after receiving a Delist Determination Letter on April 27, 2026, triggered by its common stock bid price closing below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). This follows the Company's placement under a one-year Discretionary Panel Monitor on February 3, 2026, pursuant to Rule 5815(d)(4)(A), which severely restricts remediation options. If found non-compliant again during monitoring, Curis cannot submit a compliance plan, receive extensions, or benefit from cure periods under Rule 5810(c). Instead, delisting proceeds directly to a hearing opportunity with the Nasdaq Hearings Panel. The Company plans to appeal by the May 4, 2026 deadline, staying suspension scheduled for May 6, 2026 opening. However, success is uncertain, and failure could result in transfer to over-the-counter trading, increasing liquidity risks, volatility, and institutional selling pressure for investors. This event underscores ongoing compliance challenges and potential long-term listing instability.